On March 3, 2021, SciClone Pharmaceuticals (Holdings) Limited (hereinafter referred to as "Saison Pharmaceuticals") issued approximately 116 million shares (excluding the over-allotment part) worldwide and listed on the main board of the Stock Exchange of Hong Kong at an issue price of HK $18.80 per share, raising more than HK $2 billion from investors.
SciClone Pharmaceuticals is a biopharmaceutical company with an integrated platform for product development and commercialization. The company is strategically focused on some of China's largest and rapidly growing medical needs, including in the areas of oncology and severe infections. With its integrated platform, SciClone Pharmaceuticals seeks to develop and commercialize a combination of quality marketed products (including its own product, Ridaxian) and drugs under development in key therapeutic areas. Its core self-owned product, Ridaxian (a new original drug based on the thymus method), played an important role in preventing and treating SARS in 2003 and 2020, and is widely used in the combined treatment of hepatitis B, sepsis and tumor.
JunHe acted as the co-sponsors and underwriter’s PRC legal counsel of this Project and provided high quality, rigorous and efficient legal services. JunHe’s team overcame the many adverse effects of the epidemic and assisted the co-sponsor in carrying out due diligence. The team reviewed and amended the prospectus, the application and the offering documents related to this listing. They issued PRC legal opinions and assisted in replying to feedback questions from the Hong Kong Stock Exchange regarding PRC law. SciClone Pharmaceuticals was investigated by the SEC during its US listing and reached a settlement agreement with the SEC. The Hong Kong Stock Exchange was concerned about the potential compliance issues in its history.
JunHe assisted the Sponsor to carry out a deep examination of the situation and assisted the Sponsor to successfully reply to the feedback questions from the Stock Exchange of Hong Kong, ultimately helping Saisheng Pharmaceutical to successfully obtain the approval and consent of the listing application from the Stock Exchange of Hong Kong. JunHe 's solid work attitude and professional service won unanimous appreciation and trust from their clients and other intermediaries.
The lead partner of this Project was Mr. SHAO, Chunyang.